Elena Kuligina

Dr. Elena Kuligina

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in BioMed Research International
Verified
Journal Article
Open access
PDF file
GSGrigory Stepanov
Grigory Stepanov
JFJulia A. Filippova
Julia A. Filippova
AKAndrey Komissarov
Andrey Komissarov
EKElena Kuligina
Elena Kuligina
VRVladimir A. Richter
Vladimir A. Richter
DSDmitry V. Semenov
Dmitry V. Semenov
Small nucleolar RNAs (snoRNAs) are appreciable players in gene expression regulation in human cells. The canonical function of box C/D and box H/ACA snoRNAs is posttranscriptional modification of ribosomal RNAs (rRNAs), namely, 2′-O-methylation and pseudouridylation, respectively. A series of independent studies demonstrated that snoRNAs, as well as other noncoding RNAs, serve as the source of various short regulatory RNAs. Some snoRNAs and their fragments can also participate in the regulation of alternative splicing and posttranscriptional modification of mRNA. Alterations in snoRNA expression in human cells can affect numerous vital cellular processes. SnoRNA level in human cells, blood serum, and plasma presents a promising target for diagnostics and treatment of human pathologies. Here we discuss the relation between snoRNAs and oncological, neurodegenerative, and viral diseases and also describe changes in snoRNA level in response to artificial stress and some drugs.

Verified
Journal Article
Open access
PDF file
MDMaya A. Dymova
Maya A. Dymova
EKElena Kuligina
Elena Kuligina
VRVladimir Richter
Vladimir Richter
Glioblastoma multiforme (GBM) is the most common and fatal primary brain tumor, is highly resistant to conventional radiation and chemotherapy, and is not amenable to effective surgical resection. The present review summarizes recent advances in our understanding of the molecular mechanisms of therapeutic resistance of GBM to already known drugs, the molecular characteristics of glioblastoma cells, and the barriers in the brain that underlie drug resistance. We also discuss the progress that has been made in the development of new targeted drugs for glioblastoma, as well as advances in drug delivery across the blood–brain barrier (BBB) and blood–brain tumor barrier (BBTB).

1 January 2017 in BioMed Research International
Verified
Journal Article
Open access
PDF file
ASAnna V. Savelyeva
Anna V. Savelyeva
EKElena Kuligina
Elena Kuligina
DBDmitry N. Bariakin
Dmitry N. Bariakin
VKVadim V. Kozlov
Vadim V. Kozlov
ERElena Ryabchikova
Elena Ryabchikova
DSDmitry V. Semenov
Dmitry V. Semenov
Human peripheral blood contains RNA in cells and in extracellular membrane vesicles, microvesicles and exosomes, as well as in cell-free ribonucleoproteins. Circulating mRNAs and noncoding RNAs, being internalized, possess the ability to modulate vital processes in recipient cells. In this study, with SOLiD sequencing technology, we performed identification, classification, and quantification of RNAs from blood fractions: cells, plasma, plasma vesicles pelleted at 16,000gand 160,000g, and vesicle-depleted plasma supernatant of healthy donors and non-small cell lung cancer (NSCLC) patients. It was determined that 16,000gblood plasma vesicles were enriched with cell-free mitochondria and with a set of mitochondrial RNAs. The variable RNA set of blood plasma 160,000gpellets reflected the prominent contribution of U1, U5, and U6 small nuclear RNAs’ fragments and at the same time was characterized by a remarkable depletion of small nucleolar RNAs. Besides microRNAs, the variety of fragments of mRNAs and snoRNAs dominated in the set of circulating RNAs differentially expressed in blood fractions of NSCLC patients. Taken together, our data emphasize that not only extracellular microRNAs but also circulating fragments of messenger and small nuclear/nucleolar RNAs represent prominent classes of circulating regulatory ncRNAs as well as promising circulating biomarkers for the development of disease diagnostic approaches.

2 November 2018 in Genes
Verified
Journal Article
Open access
PDF file
GSGrigory Stepanov
Grigory Stepanov
EZEvgenii Sergeevich Zhuravlev
Evgenii Sergeevich Zhuravlev
VSVictoria O. Shender
Victoria O. Shender
Anna NushtaevaAnna Nushtaeva
Anna Nushtaeva
EBEvgenia Balakhonova
Evgenia Balakhonova
VRVladimir Richter
Vladimir Richter
Short nuclear regulatory RNAs play a key role in the main stages of maturation of the precursors of the major RNA species. Small nuclear RNAs (snRNAs) form the core of the spliceosome and are responsible for the splicing of pre-mRNA molecules. Small nucleolar RNAs (snoRNAs) direct post-transcriptional modification of pre-rRNAs. A promising strategy for the development of non-coding RNA (ncRNAs) mimicking molecules is the introduction of modified nucleotides, which are normally present in natural ncRNAs, into the structure of synthetic RNAs. We have created a set of snoRNAs and snRNA analogs and studied the effect of base modifications, specifically, pseudouridine (Ψ) and 5-methylcytidine (m5C), on the immune-stimulating and cytotoxic properties of these RNAs. Here, we performed a whole-transcriptome study of the influence of synthetic snoRNA analogs with various modifications on gene expression in human cells. Moreover, we confirmed the role of PKR in the recognition of snoRNA and snRNA analogs using the short hairpin RNA (shRNA) technique. We believe that the data obtained will contribute to the understanding of the role of nucleotide modification in ncRNA functions, and can be useful for creating the agents for gene regulation based on the structure of natural snoRNAs and snRNAs.

30 September 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
GKGalina Kochneva
Galina Kochneva
GSGalina Sivolobova
Galina Sivolobova
AGAntonina Grazhdantseva
Antonina Grazhdantseva
OTOlga Troitskaya
Olga Troitskaya
Anna NushtaevaAnna Nushtaeva
Anna Nushtaeva
Olga KovalOlga Koval
Olga Koval
Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy

7 April 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Olga KovalOlga Koval
Olga Koval
ATAnastasiya V. Tkachenko
Anastasiya V. Tkachenko
AFAlexandr S. Fomin
Alexandr S. Fomin
DSDmitry V. Semenov
Dmitry V. Semenov
Anna NushtaevaAnna Nushtaeva
Anna Nushtaeva
VRVladimir A. Richter
Vladimir A. Richter
Lactaptin, the proteolytic fragment of human milk kappa-casein, induces the death of various cultured cancer cells. The mechanisms leading to cell death after lactaptin treatment have not been well characterized. In this study the in vivo and in vitro effects of a recombinant analogue of lactaptin (RL2) were examined. Following treatment with the recombinant analogue of lactaptin strong caspase -3, -7 activation was detected. As a consequence of caspase activation we observed the appearance of a sub-G1 population of cells with subdiploid DNA content. Dynamic changes in the mRNA and protein levels of apoptosis-related genes were estimated. No statistically reliable differences in p53 mRNA level or protein level were found between control and RL2-treated cells. We observed that RL2 constitutively suppressed bcl-2 mRNA expression and down regulated Bcl-2 protein expression in MDA-MB-231 cells. We demonstrated that RL2 penetrates cancer and non-transformed cells. Identification of the cellular targets of the lactaptin analogue revealed that α/β-tubulin and α-actinin-1 were RL2-bound proteins. As the alteration in cellular viability in response to protein stimulus can be realized not only by way of apoptosis but also by autophagy, we examined the implications of autophagy in RL2-dependent cell death. We also found that RL2 treatment induces LC3-processing, which is a hallmark of autophagy. The autophagy inhibitor chloroquine enhanced RL2 cytotoxicity to MDA-MB-231 cells, indicating the pro-survival effect of RL2-dependent autophagy. The antitumour potential of RL2 was investigated in vivo in mouse xenografts bearing MDA-MB-231 cells. We demonstrated that the recombinant analogue of lactaptin significantly suppressed the growth of solid tumours. Our results indicate that lactaptin could be a new molecule for the development of anticancer drugs.